The combination of CJC-1295 No DAC and Ipamorelin represents a dual-action growth hormone secretagogue protocol widely evaluated in preclinical literature. By simultaneously targeting the growth hormone-releasing hormone (GHRH) receptor and the growth hormone secretagogue receptor (GHS-R1a), this co-administration stimulates additive, pulsatile growth hormone release without elevating baseline cortisol or prolactin.
The combination of CJC-1295 No DAC and Ipamorelin represents a dual-action growth hormone secretagogue protocol widely evaluated in preclinical literature. By simultaneously targeting the growth hormone-releasing hormone (GHRH) receptor and the growth hormone secretagogue receptor (GHS-R1a), this co-administration stimulates additive, pulsatile growth hormone release without elevating baseline cortisol or prolactin.
In neuroendocrine research, growth hormone (GH) secretion from the anterior pituitary gland is natively regulated by two distinct signal transduction pathways. Growth hormone-releasing hormone (GHRH) binds to GHRH receptors (GHRH-R) on somatotrophs, activating adenylate cyclase and boosting intracellular cyclic adenosine monophosphate (cAMP). Concurrently, ghrelin or growth hormone-releasing peptides (GHRPs) bind to the growth hormone secretagogue receptor (GHS-R1a), triggering the phospholipase C (PLC) pathway and mobilizing intracellular calcium ions (Ca2+).
When researchers co-administer a GHRH analog alongside a GHRP, these two signal transduction pathways converge downstream inside the pituitary somatotroph. Preclinical models demonstrate that activating both cAMP- and Ca2+-dependent cascades simultaneously produces a synergistic release of endogenous growth hormone that significantly exceeds the mathematical sum of either peptide evaluated independently. Investigating the cjc 1295 no dac ipamorelin blend allows researchers to observe this physiological mechanism within controlled laboratory environments.
To explore detailed background literature on secretagogue interactions, researchers can navigate the broader PX1 research library for foundational studies on somatotroph signaling kinetics.
CJC-1295 No DAC, structurally identified as Modified GRF 1-29 (Mod GRF 1-29), is a truncated, tetrasubstituted 29-amino-acid synthetic peptide derived from native GHRH(1-29). Native GHRH is rapidly cleaved in vivo by the enzyme dipeptidyl peptidase IV (DPP-IV) at the Ala2 site. Mod GRF 1-29 incorporates specific amino acid substitutions—specifically D-Ala2, Gln8, Ala15, and Leu27—that protect the peptide backbone against enzymatic degradation while preserving receptor binding affinity.
Unlike CJC-1295 with DAC (Drug Affinity Complex), which binds covalently to serum albumin to prolong its elimination half-life over several days, CJC-1295 No DAC exhibits a short terminal half-life of approximately 30 minutes in animal models. Studied as a long-acting growth-hormone-releasing hormone that sustains GH and downstream IGF-1 levels for tissue repair research, Mod GRF 1-29 evokes discrete, physiological pulses of GH rather than continuous, tonic elevation. This short-acting profile makes it an ideal candidate for protocols evaluating natural circadian somatotrophic rhythms.
Researchers seeking pure individual reference standards can examine single-entity CJC-1295 No DAC samples verified for structural sequence fidelity.
Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) classified as a second-generation growth hormone secretagogue. It acts as a highly selective agonist of the GHS-R1a receptor. Early-generation secretagogues such as GHRP-6 and GHRP-2 frequently cause off-target stimulation of the central nervous system, prompting unwanted elevations in plasma adrenocorticotropic hormone (ACTH), cortisol, and prolactin.
In contrast, in vitro pituitary cell assays and in vivo animal models demonstrate that Ipamorelin stimulates somatotroph GH release with exceptional receptor selectivity. Even at high experimental dosages, Ipamorelin maintains negligible affinity for receptors governing ACTH or prolactin release. This selectivity preserves baseline endocrine stability, allowing investigative teams to isolate growth-axis downstream effects without confounding glucocorticoid or prolactin interference.
Individual batches of high-purity Ipamorelin are available for targeted single-pathway validation assays.
To select the appropriate secretagogue combination for a given experimental model, laboratory teams must analyze how CJC-1295 No DAC and Ipamorelin differ from alternative GHRH analogs and GHRP variants. The choice of secretagogue dictates whether GH release occurs as a discrete physiological spike or a prolonged background elevation.
For instance, Sermorelin is the un-substituted, native 29-amino-acid GHRH sequence. While effective, it exhibits a shorter plasma half-life than Mod GRF 1-29 due to rapid cleavage by DPP-IV. On the long-acting end of the spectrum, CJC-1295 DAC forms covalent bonds with circulating albumin, elevating baseline GH and IGF-1 continuously for days. While beneficial in specific long-term catabolic studies, continuous GH elevation can downregulate pituitary GHRH receptors over extended periods.
Similarly, comparing Ipamorelin to broader secretagogue categories shows distinct signaling differences. Researchers studying generalized secretagogue dynamics can consult our comprehensive overview of growth hormone secretagogues to review relative receptor affinities and signaling kinetics.
Endogenous growth hormone secretion in mammals is inherently pulsatile, characterized by episodic secretory bursts separated by periods of low baseline concentration. This pulsatility is critical for maintaining receptor sensitivity in target tissues, such as hepatocytes, skeletal muscle cells, and osteoblasts.
Co-administering CJC-1295 No DAC with Ipamorelin closely mimics this physiological pulsatility. Because neither compound possesses a prolonged serum half-life, their combined application delivers a focused signal to the pituitary, resulting in a pronounced GH pulse that decays within 2 to 3 hours. This return to baseline prevents continuous receptor occupation, avoiding the down-regulation of GHRH receptors or somatostatin-mediated negative feedback loops associated with continuous tonic GH exposure ('GH bleed').
Protocols aimed at evaluating cellular recovery, gene transcription, or metabolic signaling often prefer short-acting dual-secretagogue models to preserve end-target receptor responsiveness across multi-week animal studies.
When growth hormone is released from anterior pituitary somatotrophs, it enters systemic circulation and binds to GH receptors on target cells, predominantly in the liver. This binding activates the JAK2/STAT5 signaling pathway, inducing the transcription and systemic release of Insulin-like Growth Factor 1 (IGF-1), alongside local IGF-1 autocrine/paracrine expression in connective tissues.
In preclinical rodent models of musculoskeletal injury, elevated circulating IGF-1 accelerates cellular proliferation, collagen type I synthesis, and satellite cell activation in skeletal muscle tissue. Studies examining tendon and ligament healing report enhanced hydroxyproline content and improved ultimate tensile strength following co-treatment with GHRH analogs and GHRPs.
Furthermore, in vitro cell culture studies indicate that synergistic GH/IGF-1 signaling upregulates amino acid transport and nitrogen retention, key markers of cellular protein synthesis. These findings highlight the utility of dual secretagogue combinations in connective tissue regeneration and metabolic homeostasis research.
Proper handling and reconstitution techniques are imperative to maintain peptide structural integrity and yield reproducible experimental data. Synthetic peptides are delivered as lyophilized (freeze-dried) cakes or powders, which require careful reconstitution using sterile solvents.
To reconstitute lyophilized CJC-1295 No DAC / Ipamorelin blends, researchers typically use bacteriostatic water (0.9% benzyl alcohol preserved). The solvent should be introduced slowly down the internal glass wall of the vial to prevent turbulent splashing, which can denature the tertiary structure of fragile peptide chains. The vial should be gently swirled rather than vigorously shaken.
Following reconstitution, liquid solutions should be aliquoted to avoid repeated freeze-thaw cycles and stored under refrigeration at 2°C to 8°C for short-term assays (up to 30 days) or maintained at -20°C to -80°C for extended storage. For detailed preparation guidelines across multiple compound classes, visit our general catalog of all research peptides.
Experimental integrity depends entirely on the purity and chemical consistency of research reagents. Low-grade or improperly synthesized peptides can introduce sequence truncations, residual organic solvents, or bacterial endotoxins that invalidate assay results and damage cell cultures.
PX1 Research enforces stringent analytical quality standards for every lot manufactured. Primary purity is verified using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC), ensuring a minimum purity threshold of 99.0%. Mass Spectrometry (MS) is conducted concurrently to confirm correct molecular mass and primary amino acid sequence identity.
Because bacterial endotoxins (lipopolysaccharides) induce inflammatory cascades in cellular and animal models, all PX1 lots undergo Chromogenic LAL (Limulus Amebocyte Lysate) testing to guarantee endotoxin levels remain strictly below regulatory thresholds (<0.01 EU/mg). Testing is executed in ISO 17025 accredited analytical laboratories operating under GMP-compliant quality management systems.
PX1 Research serves as a trusted domestic supplier of research-grade peptides for academic, institutional, and biotechnology laboratories across the United States. All products are manufactured in US facilities, eliminating international supply chain vulnerabilities and ensuring strict compliance with domestic quality standards.
Every standard product order and bulk custom synthesis order includes lot-specific Certificates of Analysis (COAs) accessible directly through our system. PX1 ships directly from California and Arizona facilities with same-day order processing for orders placed Monday through Friday.
Principal investigators and laboratory procurement officers seeking high-volume orders or tailored analytical reporting can establish a dedicated account through our wholesale peptide program.
What is CJC-1295 No DAC Ipamorelin?
It is a research compound co-formulation consisting of Modified GRF 1-29 (a short-acting GHRH analog) and Ipamorelin (a selective ghrelin/GHRP agonist), designed to evaluate synergistic growth hormone secretagogue signaling in vitro and in preclinical animal models.
How does CJC-1295 No DAC differ from CJC-1295 with DAC?
CJC-1295 No DAC lacks the Drug Affinity Complex (DAC) moiety. As a result, it has a short serum half-life (~30 minutes) and induces discrete, pulsatile GH release. CJC-1295 with DAC binds to serum albumin, extending its half-life to several days and causing continuous, baseline GH elevation.
Why pair a GHRH analog with a GHRP like Ipamorelin in research?
GHRH analogs activate the cAMP/PKA signaling pathway, while GHRPs activate the intracellular Ca2+/PLC pathway in pituitary somatotrophs. Co-activation of these complementary pathways produces a synergistic GH release greater than the additive effect of either peptide alone.
Does Ipamorelin increase cortisol or prolactin levels?
In preclinical studies, Ipamorelin demonstrates high selectivity for the GHS-R1a receptor and does not significantly stimulate ACTH, cortisol, or prolactin secretion, unlike older GHRPs such as GHRP-2 or GHRP-6.
What reconstituted storage conditions are required for this blend?
Once reconstituted with bacteriostatic water, liquid solutions should be stored at 2°C to 8°C for short-term use (up to 30 days) or aliquoted and stored at -20°C to -80°C to prevent degradation over long periods.
How is the purity of PX1 Research peptides verified?
Every lot undergoes independent ISO 17025 laboratory testing using RP-HPLC (to confirm purity >99.0%), Mass Spectrometry (to confirm molecular weight/sequence), and Chromogenic LAL testing (to verify low endotoxin content).
Are PX1 Research compounds suitable for human consumption?
No. All products supplied by PX1 Research are intended strictly for laboratory research, in vitro assays, and preclinical animal studies. They are not for human or veterinary use, therapy, diagnosis, or administration.
Where are PX1 Research compounds manufactured and shipped from?
PX1 Research compounds are manufactured in US-based GMP-compliant facilities and shipped directly from fulfillment centers in California and Arizona with same-day dispatch for weekday orders.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.